The CU Technology Transfer Office (TTO) announced two new U.S. patents awarded to researchers at CU Anschutz.
One patent was awarded to a team led by Richard Johnson, MD, School of Medicine, Renal Medicine Division, for a method of preventing or treating metabolic syndrome which is a set of medical conditions associated with later development of diabetes, cardiovascular disease, heart failure and kidney disease.
TTO began pursing this patent on behalf of the university in January 2010; the patent (U.S. 8,697,628, “Methods of Using AMPD2 Inhibitors for the Treatment of Fatty Liver, Obesity and Diabetes”) was granted on April 15, 2014.
Other inventors on the patent are Drs. Gabriela Garcia, Christopher Rivard and Miguel Lanaspa-Garcia–all Renal Medicine.
In a different research area, a second patent was awarded to a team led by John Carpenter, PhD, Skaggs School of Pharmacy and Pharmaceutical Sciences; Theodore Randolph at CU-Boulder, ChBE, and CU-based company BaroFold, Inc.
This patent is on an approach for improving protein-based drug formulations (used to treat cancers, infectious diseases and several other diseases). The invention reduces sub-visible particles that can cause adverse immune responses in the patient.
The patent (U.S. 8,697,848, “Method for Reducing Immunogenicity of Therapeutic Protein Compositions”) was issued on April 15, 2014, with a related patent application pending in the U.S. and patent protection also being sought in Europe and Canada.
Prosecution for this patent family began in July 2010. Other inventors on the patent are ChBE doctoral graduates Amber (Haynes) Fradkin and Matthew Seefeldt (now president of BaroFold).